Foamable liquid oral composition and oral product

Abstract

To provide a foamable liquid oral composition that exhibits superior retention of fluoride ions and long-lasting foaming.SOLUTION: The present invention provides a foamable liquid oral composition to be applied in a foamed state, the composition comprising: a component (A): sodium fluoride; a component (B): a water-soluble calcium salt; a component (C): at least one selected from the group consisting of condensed phosphates and salts thereof; and a component (D): at least one selected from nonionic surfactants having an amide group and amphoteric surfactants.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a foaming liquid oral composition and an oral product.

Background Art

[0002] Fluorides such as sodium fluoride are widely used as medicinal components in oral compositions such as dentifrices because of their caries-preventive effect. To effectively actuate fluorides, it is effective to retain fluoride ions on the oral mucosa and tooth surfaces for a long time, and it is desirable to leave a large amount of fluoride ions in the oral cavity even after rinsing the oral cavity with water or gargling after use. Patent Document 1 discloses a method of coexisting calcium ions, fluoride ions, and phosphate ions as a method for improving the retention of fluoride ions.

[0003] On the other hand, among liquid oral compositions, there is a type that is used in a foamed state by using a foam discharge container having a foaming mechanism or by making it foamed by gargling or the like in the oral cavity. For such types of oral compositions, good foaming and foam persistence are required. Patent Document 2 discloses a foamed oral product in which a liquid oral composition containing a hydrophobic active ingredient, an anionic surfactant or an amphoteric surfactant, a polyoxyethylene alkyl ether, and a water-soluble polymer having a hydroxy group is housed in a foam discharge container.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0005] Foamy oral compositions are likely to spread in the oral cavity even with gentle brushing. Therefore, a foamy oral composition containing fluoride is considered effective for preventing tooth decay in caregivers with impaired oral function, children who cannot brush their teeth, etc. However, according to the study by the present inventor, when applying the technique of Patent Document 1 to a foamy oral composition in order to enhance the retention of fluoride ions, the persistence of the foam may decrease. Furthermore, when a liquid oral composition is made foamy with a foam discharge container, the filter of the foam discharge container may become clogged during repeated discharges, and the foamy oral composition may not be discharged.

[0006] An object of the present invention is to provide a foaming liquid oral composition and an oral product that are excellent in fluoride ion retention and foam persistence.

Means for Solving the Problems

[0007] As a result of intensive studies, the present inventor has found that the above problems can be solved by combining sodium fluoride, a water-soluble calcium salt, a condensed phosphoric acid or its salt, and a specific surfactant. The present invention is based on the above findings and has the following aspects.

[0008] <1> A foaming liquid oral composition to be used in a foamed state, (A) component: sodium fluoride and, (B) component: a water-soluble calcium salt and, (C) component: at least one selected from the group consisting of condensed phosphoric acid and its salts, and (D) component: at least one selected from the group consisting of a nonionic surfactant having an amide group and an amphoteric surfactant, A foaming liquid oral composition containing the same. <2> The foaming liquid oral composition according to <1>, wherein the (B) component is at least one selected from the group consisting of calcium chloride, calcium gluconate, calcium lactate, calcium glycerophosphate, and calcium pantothenate. <3> The foaming liquid oral composition according to <1> or <2>, wherein the component (C) is at least one selected from the group consisting of pyrophosphoric acid and its alkali metal salts. <4> The foaming liquid oral composition according to any one of <1> to <3>, wherein the component (D) is at least one selected from the group consisting of fatty acid diethanolamide, fatty acid monoethanolamide, alkyl betaine, fatty acid amide propyl betaine, alkyl imidazolinium betaine, and 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine. <5> The foaming liquid oral composition according to any one of <1> to <4>, wherein the mass ratio of the component (D) to the component (B) is 0.02 to 25. <6> (E) component: Further containing water, The foaming liquid oral composition according to any one of <1> to <5>, wherein the content of the component (E) is 70 to 95% by mass based on the total mass of the foaming liquid oral composition. <7> An oral product having the foaming liquid oral composition according to any one of <1> to <6>, and a foam discharge container for containing the foaming liquid oral composition.

Advantages of the Invention

[0009] According to the present invention, it is possible to provide a foaming liquid oral composition and an oral product that are excellent in fluorine ion retention and foam persistence.

Modes for Carrying Out the Invention

[0010] In this specification, the "oral composition" means a composition mainly intended for use in the oral cavity. The "foaming liquid oral composition" means a liquid oral composition used in a foamed state. "Water-soluble" means that the solubility in water at 20 °C is 1 g / 100 g or more. The "~" indicating a numerical range means that the numerical values described before and after it are included as the lower limit value and the upper limit value.

[0011] [Foaming liquid oral composition] The foaming liquid oral composition of the present invention (hereinafter, also simply referred to as "liquid oral composition") contains component (A), component (B), component (C), and component (D).

[0012] <Component (A)> Component (A) is sodium fluoride (NaF). When the liquid oral composition contains component (A), fluoride ions stay on the tooth surface and exhibit an anti-caries effect.

[0013] <Component (B)> Component (B) is a water-soluble calcium salt. When the liquid oral composition contains component (B), the retention of fluoride ions on the tooth surface is improved.

[0014] Examples of component (B) include calcium chloride, calcium nitrate, calcium acetate, calcium citrate, calcium gluconate, calcium benzoate, calcium formate, calcium fumarate, calcium lactate, calcium glycerophosphate, calcium butyrate, calcium isobutyrate, calcium malate, calcium maleate, calcium propionate, calcium valerate, calcium pantothenate, and the like. As component (B), at least one selected from the group consisting of calcium chloride, calcium gluconate, calcium lactate, calcium glycerophosphate, and calcium pantothenate is preferable, and at least one selected from the group consisting of calcium chloride, calcium gluconate, calcium lactate, and calcium glycerophosphate is particularly preferable. Component (B) may be used alone or in combination of two or more.

[0015] <Component (C)> Component (C) is at least one selected from the group consisting of condensed phosphoric acid and its salts. When the liquid oral composition contains the component (C), the retention of fluoride ions on the tooth surface is improved.

[0016] Examples of the condensed phosphoric acid include linear polyphosphoric acids such as pyrophosphoric acid, tripolyphosphoric acid, and tetrapolyphosphoric acid, and cyclic polyphosphoric acids such as trimeta phosphoric acid and tetrameta phosphoric acid. The degree of polymerization of the condensed phosphoric acid is, for example, 2 to 6. Examples of the salt of the condensed phosphoric acid include alkali metal salts such as sodium salt and potassium salt. As the component (C), at least one selected from the group consisting of pyrophosphoric acid, tripolyphosphoric acid, and their alkali metal salts is preferable, at least one selected from the group consisting of pyrophosphoric acid and its alkali metal salts is more preferable, and at least one selected from the group consisting of pyrophosphoric acid, potassium pyrophosphate, and sodium pyrophosphate is particularly preferable. The component (C) may be used alone or in combination of two or more.

[0017] <(Component D)> The component (D) is at least one selected from nonionic surfactants having an amide group and amphoteric surfactants. When the liquid oral composition contains the component (D), the foaming property, the persistence of the foam, and the discharge property from the foam discharge container are improved.

[0018] As the component (D), it can be appropriately selected from known nonionic surfactants having an amide group and amphoteric surfactants. As the nonionic surfactant having an amide group, a fatty acid alkanolamide type nonionic surfactant is preferable. Examples of the fatty acid alkanolamide type nonionic surfactant include fatty acid alkanolamides and their alkylene oxide adducts. The number of carbon atoms of the fatty acid residue in the fatty acid alkanolamide is, for example, 5 to 19. The fatty acid residue is the part obtained by removing the carboxy group from the fatty acid. The number of carbon atoms of the alkanol group (hydroxyalkyl group) is, for example, 2 to 3. The alkanol group may have a linear structure or a branched chain structure. In the alkylene oxide adduct, examples of the alkylene oxide include ethylene oxide and propylene oxide. The average number of moles of added alkylene oxide is, for example, 2 to 11. As the fatty acid alkanolamide type nonionic surfactant, fatty acid diethanolamides such as coconut oil fatty acid diethanolamide and fatty acid monoethanolamides such as coconut oil fatty acid monoethanolamide are preferable. Among these, from the viewpoint of low irritation, fatty acid diethanolamide is preferable, and coconut oil fatty acid diethanolamide is more preferable.

[0019] As the amphoteric surfactant, at least one selected from the group consisting of betaine acetate type amphoteric surfactants and imidazolinium betaine type (alkylimidazole type) amphoteric surfactants is preferable. Examples of the betaine acetate type amphoteric surfactant include alkylbetaines such as lauryldimethylaminoacetate betaine; fatty acid amide propylbetaines such as coconut oil fatty acid amide propylbetaine. Examples of the imidazolinium betaine type amphoteric surfactant include alkylimidazolinium betaine and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine. In these compounds, the number of carbon atoms of the alkyl group is, for example, 11 to 17. Among the above, as the amphoteric surfactant, from the viewpoint of foaming property, the imidazolinium betaine type amphoteric surfactant is preferable, and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine is more preferable.

[0020] (D) component is preferably at least one selected from the group consisting of fatty acid alkanolamide type nonionic surfactants, betaine acetate type amphoteric surfactants, and imidazolinium betaine type amphoteric surfactants. More preferably, it is at least one selected from the group consisting of fatty acid diethanolamide, fatty acid monoethanolamide, alkyl betaine, fatty acid amide propyl betaine, alkyl imidazolinium betaine, and 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine. Particularly preferred is 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine.

[0021] <Content of each component> The content of component (A) is preferably 0.09 to 1.3% by mass, more preferably 0.10 to 1.1% by mass, based on the total mass of the liquid oral composition. When the content of component (A) is at least the above lower limit value, the fluorine ion retention property is more excellent. When the content of component (A) is at most the above upper limit value, the occurrence of harmful effects such as mottled teeth due to excessive intake can be suppressed.

[0022] The content of component (B) is preferably 0.02 to 5.0% by mass, more preferably 0.03 to 3.0% by mass, based on the total mass of the liquid oral composition. When the content of component (B) is at least the above lower limit value, the fluorine ion retention property and the discharge property from the foam discharge container are more excellent. When the content of component (B) is at most the above upper limit value, the fluorine ion retention property and the foam persistence are more excellent.

[0023] The content of component (C) is preferably 0.02 to 3.0% by mass, more preferably 0.03 to 1.3% by mass, based on the total mass of the liquid oral composition. When the content of component (C) is at least the above lower limit value, the fluorine ion retention property is more excellent. When the content of component (C) is at most the above upper limit value, the discharge property from the foam discharge container is more excellent.

[0024] The content of component (D) is preferably 0.005 to 1.0% by mass, more preferably 0.05 to 0.8% by mass, based on the total mass of the liquid oral composition. When the content of component (D) is at least the above lower limit, the foaming property, the persistence of foam, and the discharge property from the foam discharge container are more excellent. When the content of component (D) is at most the above upper limit, it is easy to make the value of (D) / (B) described later not exceed the preferable upper limit.

[0025] The mass ratio of component (D) to component (B) (hereinafter also referred to as "(B) / (D)") is preferably 0.02 to 25, more preferably 0.1 to 10. When (B) / (D) is at least the above lower limit, it is possible to suppress the inhibition of foaming by component (B), and the persistence of foam is improved. When (B) / (D) is at most the above upper limit, it is possible to suppress the precipitation of calcium salts during storage of the liquid oral composition, suppress the clogging of the filter of the foam discharge container by the calcium salts, and the discharge property from the foam discharge container becomes good. Furthermore, surprisingly, the fluoride ion retention property is also improved.

[0026] The molar ratio of component (B) to component (A) (hereinafter also referred to as "(B) / (A)") is preferably 0.005 to 10.0, more preferably 0.01 to 5.0. When (B) / (A) is at least the above lower limit, the fluoride ion retention property is more excellent. When (B) / (A) is at most the above upper limit, the fluoride ion retention property is more excellent.

[0027] The molar ratio of component (C) to component (A) (hereinafter also referred to as "(C) / (A)") is preferably 0.005 to 2.1, more preferably 0.01 to 2.1. When (C) / (A) is at least the above lower limit, the fluoride ion retention property is more excellent. When (C) / (A) is at most the above upper limit, the fluoride ion retention property is more excellent.

[0028] <Component (E)> The liquid oral composition typically further contains component (E). Component (E): water. Examples of component (E) include purified water, sterilized purified water, water for injection, and the like.

[0029] When the liquid oral composition contains the component (E), the content of the component (E) is preferably 70% by mass or more, more preferably 75% by mass or more, and even more preferably 80% by mass or more based on the total mass of the liquid oral composition. The upper limit of the content of the component (E) is, for example, 95% by mass. When the content of the component (E) is at least the above lower limit value, the discharge property from the foam discharge container is more excellent.

[0030] <Other components> The liquid oral composition may further contain other components other than the component (A), the component (B), the component (C), the component (D), and the component (E). The other components can be appropriately selected from known components in consideration of the usage method of the liquid oral composition and the like. Examples of the other components include abrasives, binders, thickeners, surfactants other than the component (D), colorants, sweeteners, preservatives, fragrances, active ingredients, and pH adjusters.

[0031] Examples of the abrasive include silica-based abrasives such as anhydrous silicic acid, precipitated silica, silica gel, aluminosilicate, and zirconosilicate, dicalcium phosphate dihydrate and anhydride, monocalcium phosphate, tricalcium phosphate, tetracalcium phosphate, calcium carbonate, calcium hydroxide, aluminum hydroxide, insoluble sodium metaphosphate, magnesium phosphate tribasic, and magnesium carbonate. From the viewpoint of the discharge property from the foam discharge container, the content of the abrasive is preferably 0.5% by mass or less, more preferably 0.4% by mass or less, and particularly preferably 0% by mass based on the total mass of the liquid oral composition. That is, it is particularly preferable that the liquid oral composition does not contain an abrasive.

[0032] Examples of the binder include organic binders selected from water-soluble polymer substances such as cellulose derivatives such as sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, gums such as xanthan gum, tragacanth gum, karaya gum, gum arabic, and polyacrylates such as sodium polyacrylate, thickening silica, inorganic binders such as thickening aluminum silica, Veegum, and laponite. The content of the binder is preferably 0 to 0.3% by mass, more preferably 0 to 0.2% by mass, based on the total mass of the liquid oral composition.

[0033] Examples of the thickener include sugar alcohols such as sorbitol, xylitol, erythritol, and maltitol, polyhydric alcohols such as glycerin, propylene glycol, and polyethylene glycol having an average molecular weight of 160 to 400 (average molecular weight described in the 2006 Pharmaceutical Excipients Standard). The content of the thickener is preferably 1 to 25% by mass, more preferably 5 to 20% by mass, based on the total mass of the liquid oral composition.

[0034] Examples of the surfactant other than the component (D) include nonionic surfactants and anionic surfactants other than the component (D). Examples of the nonionic surfactant other than the component (D) include glycerin fatty acid esters such as decaglycerin laurate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate (average number of moles of ethylene oxide added (hereinafter abbreviated as "E.O.") 20), alkyl glycosides having 12 to 16 carbon atoms in the alkyl group, sorbitan fatty acid esters such as sorbitan tristearate, sucrose fatty acid esters such as sucrose laurate, and polyoxyethylene alkyl ethers such as polyoxyethylene stearyl ether (E.O. 6). Examples of anionic surfactants include alkyl sulfates such as sodium lauryl sulfate and sodium myristyl sulfate, acyl sarcosinates such as sodium lauroyl sarcosinate, acyl amino acid salts such as sodium acyl glutamate, sodium acyl taurine, sodium dodecylbenzenesulfonate, sodium lauryl sulfoacetate, and sodium α-olefin sulfonate. The content of surfactants other than the component (D) is preferably 0.01 to 1.5% by mass, more preferably 0.01 to 1.0% by mass, based on the total mass of the liquid oral composition.

[0035] Examples of colorants include Red No. 2, Red No. 3, Red No. 225, Red No. 226, Yellow No. 4, Yellow No. 5, Yellow No. 205, Blue No. 1, Blue No. 2, Blue No. 201, Blue No. 204, Green No. 3, mica titanium, and titanium oxide. Examples of sweeteners include sodium saccharin, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidin dihydrochalcone, and perillartine. Examples of preservatives include paraoxybenzoic acid esters such as methyl paraben, ethyl paraben, and butyl paraben, and benzoic acid or its salts such as sodium benzoate.

[0036] Examples of the fragrance include natural fragrances such as peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, mint oil, cardamom oil, coriander oil, mandarin oil, lime oil, lavender oil, rosemary oil, laurel oil, chamomile oil, caraway oil, marjoram oil, bay oil, lemongrass oil, oregano oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweety oil, pomelo oil, iris concrete, absolute peppermint, absolute rose, orange flower, and fragrances obtained by processing these natural fragrances (such as cut of the fore fraction, cut of the back fraction, fractional distillation, liquid-liquid extraction, essence formation, powder fragrance formation, etc.), menthol, carvone, anethole, cineole, methyl salicylate, cinnamic aldehyde, eugenol, 3-l-menthoxypropane-1,2-diol, thymol, linalool, linalyl acetate, limonene, menthone, menthyl acetate, N-substituted-p-menthane-3-carboxamide, pinene, octyl aldehyde, citral, pregeone, carvyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allyl cyclohexanepropionate, methyl anthranilate, ethyl methylphenylglycidate, vanillin, undecalactone, hexanal, butanol, isoamyl alcohol, hexenol, dimethyl sulfide, cyclotene, furfural, trimethylpyrazine, ethyl lactate, ethyl thioacetate, and other single-component fragrances, as well as compounded fragrances such as strawberry flavor, apple flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, fruit mix flavor, tropical fruit flavor, etc. Known fragrance materials for oral compositions can be combined and used. The content of the fragrance is not particularly limited, but the content of the above fragrance materials is preferably 0.000001 to 1% by mass based on the total mass of the liquid oral composition. The content of the flavoring fragrance using the above fragrance materials is preferably 0.05 to 2% by mass based on the total mass of the liquid oral composition.

[0037] Examples of the active ingredients include bactericides such as isopropylmethylphenol and cetylpyridinium chloride; water-soluble phosphate compounds such as potassium salts and sodium salts of orthophosphoric acid (excluding component (C)); enzymes such as dextranase, mutanase, amylase, and protease; tranexamic acid, epsilon-aminocaproic acid, triclosan, lysozyme chloride, aluminum chlorhydroxyallantoin, hinokitiol, ascorbic acid, tocopherol acetate, dihydrocholesterol, α-bisabolol, chlorhexidine salts, azulene, water-soluble copper compounds such as copper chlorophyllin sodium, chlorophyll, and copper gluconate; aluminum lactate, strontium chloride, potassium nitrate, berberine, hydroxamic acid or its derivatives, glutyl lithic acid or its salts, glycyrrhetinic acid or its derivatives, and anti-calculus agents. The above active ingredients can be incorporated in an effective amount within a range that does not interfere with the effects of the present invention.

[0038] Examples of the pH adjuster include citric acid, tartaric acid, malic acid, and salts such as potassium salts and sodium salts thereof, and sodium hydroxide.

[0039] The liquid oral composition can be prepared by a known method. For example, it can be prepared by mixing component (A), component (B), component (C), and component (D), and other components as necessary, in a conventional manner.

[0040] From the viewpoint of foamability, the viscosity of the liquid oral composition at 20°C is preferably 1.0 mPa·s to 1000 mPa·s, more preferably 1.0 mPa·s to 100 mPa·s, and even more preferably 1.0 mPa·s to 20 mPa·s. The viscosity is measured using a B-type viscometer (e.g., TVB-10M manufactured by Toki Sangyo Co., Ltd.).

[0041] In the liquid oral composition, it is preferable that fluoride ions, calcium ions, and phosphorus ions form a complex. When the complex is formed, the retention of fluoride ions in the oral cavity is improved, and thereby, the adsorption of fluoride ions to the tooth surface is further improved.

[0042] The formation of the above complex can be confirmed by observing the crystallite size by X-ray crystal structure analysis and the exothermic peak when the water of crystallization near the phosphate group desorbs at around 450 °C by calorimetry (TG-DTA measurement). That is, when the complex is formed, the crystallite size determined from the diffraction peak attributed to CaF 2 becomes less than 10 nm due to complexation with the phosphate group. Further, the occurrence of the water of crystallization peak indicates that CaF 2 is not a crystal consisting only of calcium and fluoride ions, but forms a complex in which phosphate groups interact. Specifically, when the crystallite size is less than 10 nm by the following method (1) and the presence of an exothermic peak at 450 °C is confirmed by the following method (2), the formation of the complex is confirmed. (1) Crystallite size The sample was measured with an X-ray structure diffractometer (light source Cu:Kα, 40 kV, 20 mA, divergence slit 1 / 2 deg, scattering slit 1 / 2 deg, receiving slit 0.15 mm, scan speed 4.000° / min, 2θ = 2.000 to 80.000°), and the crystallite size was calculated by the following formula (Scherrer's formula) to evaluate the presence or absence of complex formation. L = Kλ / (βcosθ) L: Crystallite size, K: Coefficient 0.9, β: Half-value width, λ: 1.54056 Å, θ: Diffraction angle (2) TG-DTA measurement (exothermic peak) Heating rate: 5 °C / min, measurement range: 25 °C to 600 °C

[0043] As a method for forming the above complex, there is no particular limitation, but when preparing a liquid oral composition, for example, it is preferable to adopt either the step of blending component (B) after blending component (A) and component (C) or the step of blending component (A) after blending component (B) and component (C). Note that when component (A) and component (B) are blended simultaneously, a part of calcium fluoride is generated, and the formation efficiency of the complex may be inferior.

[0044] <Usage method> The liquid oral composition is used in a foamed state. The foamed oral composition obtained by foaming the liquid oral composition is suitable as a foamed dentifrice composition. However, the use of the liquid oral composition is not limited thereto. For example, it can be used as various dosage forms such as a mouthwash of the type used as it is, a mouthwash of the concentrated type diluted at the time of use, a liquid dentifrice used by brushing with a toothbrush, a mouthwash, an oral spray, a gargle, an oral coolant, etc.

[0045] Examples of the method of using the liquid oral composition in a foamed state include the following methods (1) and (2). Method (1): The liquid oral composition is housed in a foam discharge container, an external force is applied to the foam discharge container to discharge the foam, and the discharged foam is applied to the oral cavity. For example, an appropriate amount of foam is discharged onto a toothbrush and used for brushing teeth. Method (2): The liquid oral composition is contained in the oral cavity and foamed in the oral cavity by gargling or the like. If necessary, the foam is used for brushing teeth.

[0046] Since the oral composition described above contains the component (A), the component (B), the component (C), and the component (D), it is excellent in fluorine ion retention and foam persistence. Also, it is excellent in dischargeability from the foam discharge container.

[0047] 〔Oral products〕 The oral product of the present invention has the foaming liquid oral composition of the present invention and a container for housing the foaming liquid oral composition.

[0048] Examples of the container include a foam discharge container, a spray discharge container, a container with a toggle cap, a container with a screw cap, a container with a push-pull cap, a container with a pump, and a refill pouch container. The foam discharge container may have a foam forming mechanism and may be of a known structure as long as it can discharge the contained liquid oral composition in a foamed state. As the foam discharging container, a non-aerosol type non-gas normal pressure container having a structure in which the content and air are mixed by applying a pressing force to the content and ejected in a foamy state from the ejection port is preferable. As such a foam discharging container, known squeeze type or pump dispenser type containers can be used. For example, a foam discharging container having the structure described in Japanese Utility Model Publication No. 7-6108, Japanese Utility Model Laid-Open No. 7-8251, and Japanese Utility Model Laid-Open No. 4-102666 can be used, and various commercially available products may also be used. The method of using an oral care product having a foam discharging container as the container is the same as the method (1) described above.

Examples

[0049] Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited to the following description. In the following examples, “%” indicates “mass %” unless otherwise specified.

[0050] <Raw materials used> Sodium fluoride: manufactured by Stella Chemifa Corporation. Calcium chloride: manufactured by Tomita Pharmaceutical Co., Ltd. Calcium gluconate: manufactured by Fuso Chemical Industry Co., Ltd. Calcium lactate: calcium lactate hydrate, manufactured by Taihei Chemical Industry Co., Ltd., trade name “Calcium Lactate”. Calcium glycerophosphate: manufactured by Iwaki Pharmaceutical Co., Ltd. Calcium pantothenate: manufactured by BASF. Potassium pyrophosphate: tetrapotassium pyrophosphate, manufactured by Taihei Chemical Industry Co., Ltd. Sodium pyrophosphate: manufactured by Taihei Chemical Industry Co., Ltd., trade name “Sodium Pyrophosphate (Anhydrous)”. Sodium tripolyphosphate: manufactured by Taihei Chemical Industry Co., Ltd. 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine: manufactured by Lion Specialty Chemicals, trade name “Enacol C-40H”. Coconut oil fatty acid diethanolamide: manufactured by Kawaken Fine Chemicals Co., Ltd. Palm oil fatty acid monoethanolamide: manufactured by Kawaken Fine Chemicals Co., Ltd. Palm oil fatty acid amidopropyl betaine: manufactured by Evonik Japan Co., Ltd. Water: purified water. Sodium lauryl sulfate: manufactured by BASF. Glycerin: manufactured by Sakamoto Yakuhin Kogyo Co., Ltd. Propylene glycol: manufactured by ADEKA Corporation. Xylitol: manufactured by Mitsubishi Corporation Foodtech Co., Ltd. Citric acid: manufactured by Komatsuya Co., Ltd. Sodium citrate: manufactured by Komatsuya Co., Ltd.

[0051] <Examples 1 to 27, Comparative Examples 1 to 4> Liquid oral compositions having the compositions shown in Tables 1 to 3 were prepared by a conventional method. An empty cell in the table indicates that the component is not blended. The obtained liquid oral composition was filled into a foam discharge container to produce an oral product. As the foam discharge container, a non-aerosol type non-gas normal pressure container (filter: 200 mesh) that mixes the content (liquid oral composition) with air by applying a pressing force to the content and discharges it in a foamy state from the ejection port was used. The following evaluations were performed on the liquid oral compositions or oral products of each example. The results are also shown in Tables 1 to 3.

[0052] (Evaluation of fluoride ion retention on enamel) A solution obtained by diluting the liquid oral composition 4-fold with purified water was vigorously stirred in a sealed container to form a foam. Approximately 1 mL of this foam was allowed to act on a 6 mm square treatment surface prepared from bovine tooth enamel for 3 minutes, and immediately washed 3 times with approximately 3 mL of purified water. After drying it, 120 μL of artificial saliva was treated on the upper surface of the section for 3 minutes, and the amount of extracted fluoride ions was measured with an ion meter (Orion 1115000 4-Star, manufactured by Thermo Fisher Scientific K.K.), and the fluoride ion concentration (ppm) (average value of N = 3) was determined and evaluated according to the following criteria. [Evaluation criteria] ◎: 0.3 ppm or more. 〇: 0.2 ppm or more and less than 0.3 ppm. △: Above 0.1 ppm and less than 0.2 ppm. ×: Less than 0.1 ppm.

[0053] (Evaluation of the Persistence of Foam during Brushing) A usage test was conducted by 9 professional panelists as follows. The foam discharged from the foam discharge container (about 0.2 mL in liquid volume) was placed on a toothbrush (product name of Lion Corporation "Clinica Advantage Hub Brush 4-row Compact Regular Type"), and brushing was performed for 3 minutes. The residual state of the foam in the oral cavity (persistence of foam) at the end of brushing was scored according to the following scoring criteria. The average score of the 9 panelists was calculated and evaluated according to the following evaluation criteria. ◎ and 〇 were regarded as passing. [Scoring Criteria for Persistence of Foam] 5 points: Foam is clearly observed. 4 points: Foam is observed. 3 points: Slightly foam is observed. 2 points: Almost no foam is observed. 1 point: No foam is observed at all. [Evaluation Criteria] ◎: The average score of 9 people is 4.5 points or more. 〇: The average score of 9 people is 4 points or more and less than 4.5 points. △: The average score of 9 people is 3 points or more and less than 4 points. ×: The average score of 9 people is less than 3 points.

[0054] (Evaluation of the Ejectability from the Foam Discharge Container) After filling the liquid oral composition into the foam discharge container, it was closed and left standing at room temperature in an upright state. Then, assuming actual use, once every week, foam with a discharge volume of 0.2 mL per discharge was discharged 3 times. The discharge rate at the 6-week (about 1.5 months) time point was calculated by the following formula. Discharge rate = {Average discharge volume at 6 weeks (g, N = 3) ÷ Average discharge volume immediately after manufacture (g, N = 3)} × 100 (%)

[0055] The ejectability was evaluated according to the following criteria. Since the discharge volume decreases when clogging occurs, the closer the discharge rate is to 100%, the better the ejectability. [Evaluation Criteria] ◎: The discharge rate is 75% or more. 〇: Spit-out rate is 50% or more and less than 75%. △: Spit-out rate is 25% or more and less than 50%. ×: Spit-out rate is less than 25%, or it no longer spits out as foam by the 6-week time point.

[0056]

Table 1

[0057]

Table 2

[0058]

Table 3

[0059] As shown in the above results, the liquid oral compositions of Examples 1 to 27 were excellent in fluoride ion retention, foam persistence, and spoutability from the foam discharge container. On the other hand, the liquid oral composition of Comparative Example 1 that did not contain the (A) component was inferior in fluoride ion retention. The liquid oral compositions of Comparative Example 2 that did not contain the (B) component and Comparative Example 3 that did not contain the (C) component were each inferior in fluoride ion retention. The liquid oral composition of Comparative Example 4 that did not contain the (D) component was inferior in foam persistence and spoutability from the foam discharge container.

Claims

1. A foaming liquid oral composition used in a foamed state, comprising: Component (A): sodium fluoride; and Component (B): a water-soluble calcium salt; and Component (C): at least one selected from the group consisting of condensed phosphoric acid and its salts; and Component (D): at least one selected from the group consisting of nonionic surfactants having an amide group and amphoteric surfactants. A foaming liquid oral composition containing the above components.

2. The foaming liquid oral composition according to Claim 1, wherein the component (B) is at least one selected from the group consisting of calcium chloride, calcium gluconate, calcium lactate, calcium glycerophosphate, and calcium pantothenate.

3. The foaming liquid oral composition according to Claim 1, wherein the component (C) is at least one selected from the group consisting of pyrophosphoric acid and its alkali metal salts.

4. The foaming liquid oral composition according to Claim 1, wherein the component (D) is at least one selected from the group consisting of fatty acid diethanolamide, fatty acid monoethanolamide, alkyl betaine, fatty acid amide propyl betaine, alkyl imidazolinium betaine, and 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine.

5. The foaming liquid oral composition according to Claim 1, wherein the mass ratio of the component (D) to the component (B) is 0.02 to 25.

6. Component (E): further containing water, The foaming liquid oral composition according to Claim 1, wherein the content of the component (E) is 70 to 95% by mass based on the total mass of the foaming liquid oral composition.

7. An oral product having the foaming liquid oral composition according to any one of Claims 1 to 6, and a foam discharge container containing the foaming liquid oral composition.

Images